
GUTS Stock Forecast & Price Target
GUTS Analyst Ratings
Bulls say
Fractyl Health Inc. is positioned favorably due to the significant surge in prescriptions for GLP-1 drugs, which have increased by 587% from 2019 to 2024, highlighting a growing market for metabolic treatments. The company's focus on developing disease-modifying therapies that address root causes of metabolic diseases aligns with this increased demand and indicates potential for substantial market penetration. Additionally, expectations of sufficient manufacturing efforts to support ongoing clinical trials suggest scalable capabilities that could enhance operational efficiency and future product delivery.
Bears say
Fractyl Health's financial outlook reveals concerns regarding its cash burn, particularly as the company increases its number of development and commercial programs, which could strain resources. Despite reporting a notable decrease in HbA1c levels from 9.6% to 7% over two years, the company's reliance on potential partner or collaborative milestone revenue remains uncertain. Additionally, while the reduction in fat mass is promising, the overall financial stability may be jeopardized without a clear path to sustainable revenue generation.
This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GUTS Analyst Forecast & Price Prediction
Start investing in GUTS
Order type
Buy in
Order amount
Est. shares
0 shares